Study type | Study design | Number (n) | Percent (%) |
---|---|---|---|
Interventional | Â | Â | Â |
Phases | |||
 | Phase 0 | 5 | 2.7 |
 | Phase 1 | 49 | 26.3 |
 | Phase 1 Phase 2 | 45 | 24.2 |
 | Phase 2 | 43 | 23.1 |
 | Phase 3 | 10 | 5.4 |
 | Phase 2 Phase 3 | 6 | 3.2 |
 | Phases 4 | 2 | 1.1 |
 | NA | 26 | 14.0 |
Allocation | |||
 | Randomized | 49 | 26.3 |
 | Non-randomized | 40 | 21.5 |
 | NA | 97 | 52.2 |
Intervention model | |||
 | Single group assignment | 103 | 55.4 |
 | Parallel assignment | 57 | 30.7 |
 | Crossover assignment | 7 | 3.8 |
 | Factorial assignment | 1 | 0.5 |
 | NA | 18 | 9.7 |
Masking | |||
 | None (Open Label) | 131 | 70.4 |
 | Single | 9 | 4.8 |
 | Triple | 9 | 4.8 |
 | Quadruple | 8 | 4.3 |
 | Double | 5 | 2.7 |
 | NA | 24 | 12.9 |
Primary purpose | |||
 | Treatment | 151 | 81.2 |
 | Prevention | 7 | 3.8 |
 | Basic science | 2 | 1.1 |
 | Device feasibility | 1 | 0.5 |
 | Supportive care | 1 | 0.5 |
 | Other | 1 | 0.5 |
 | NA | 23 | 12.4 |
Observational | |||
Observational model | |||
 | Case-Only/series | 6 | 37.5 |
 | Cohort | 3 | 18.8 |
 | Other | 3 | 18.8 |
 | NA | 4 | 25.0 |
Time perspective | |||
 | Prospective | 4 | 25.0 |
 | Other | 2 | 12.5 |
 | NA | 10 | 62.5 |